Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 30, 2017 11:45 ET | Source: NEOVACS

NEOVACS : résultats annuels 2016 et point sur les avancées opérationnelles

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} COMMUNIQUE DE PRESSE · COMMUNIQUE DE...
March 30, 2017 11:45 ET | Source: NEOVACS

NEOVACS provides corporate update and reports full year 2016 financial results

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} PRESS RELEASE · PRESS RELEASE ·...
March 20, 2017 02:30 ET | Source: NEOVACS

NEOVACS : Agenda financier 2017

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} COMMUNIQUE DE PRESSE · COMMUNIQUE DE...
March 09, 2017 08:00 ET | Source: Neovacs

Neovacs to Present IFNα Kinoid Technology and Its Clinical Outlooks at Upcoming Keystone Symposia Conference:

PARIS and BOSTON, March 09, 2017 (GLOBE NEWSWIRE) -- Neovacs (Alternext Paris:ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced that Géraldine...
March 09, 2017 01:00 ET | Source: NEOVACS

Neovacs to present IFNalpha Kinoid technology and its clinical outlooks at upcoming Keystone Symposia Conference

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} PRESS RELEASE · PRESS RELEASE · PRESS...
March 09, 2017 01:00 ET | Source: NEOVACS

Néovacs présentera la technologie de l'IFNalpha Kinoide et ses perspectives de développement clinique lors du prochain Symposium Keystone 2017

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} COMMUNIQUE DE PRESSE · COMMUNIQUE DE...
February 21, 2017 08:00 ET | Source: Neovacs

Neovacs and BioSense Sign Option Agreement Worth Up to €65 Million Plus Royalties for Chinese Development and Commercial Rights to IFNα Kinoid for Lupus and Dermatomyositis

Neovacs receives an upfront fee and is eligible for additional milestone payments and double-digit sales royalties BioSense receives option for development and commercial rights to IFNα Kinoid...
February 21, 2017 01:30 ET | Source: NEOVACS

NEOVACS AND BIOSENSE SIGN OPTION AGREEMENT WORTH UP TO €65 MILLION PLUS ROYALTIES FOR CHINESE DEVELOPMENT AND COMMERCIAL RIGHTS TO IFNalpha KINOID FOR LUPUS AND DERMATOMYOSITIS

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} PRESS RELEASE · PRESS RELEASE · PRESS...
February 21, 2017 01:30 ET | Source: NEOVACS

NEOVACS SIGNE UN CONTRAT D'OPTION DE LICENCE AVEC BIOSENSE GLOBAL LLC POUR LES DROITS DE DEVELOPPEMENT ET COMMERCIALISATION EN CHINE DE L'IFNalpha KINOIDE DANS LE LUPUS ET LA DERMATOMYOSITE

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} PRESS RELEASE · PRESS RELEASE · PRESS...
February 09, 2017 08:00 ET | Source: Neovacs

Neovacs Issued New Broad Patent in China for IFNα Kinoid

PARIS, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Neovacs (Alternext Paris:ALNEV), a leader in active immunotherapy for the treatment of autoimmune diseases, today announces that it has been granted a new...